Takeda Ventures, Inc.

Takeda Ventures, Inc. (TVI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC) a world-class pharmaceutical company and the largest in Japan. TVI (formerly Takeda Research Investment, Inc.), was founded in 2001 with the vision to extend Takeda’s reach into the Global scientific community and forge strategic relationships that complement and expand internal R&D capabilities. The change in name to Takeda Ventures, Inc. in 2011 reflects an intention to further leverage TVI’s venture networks to engage with new scientific and business avenues for Takeda, using strategic venturing to enable staged-entry into new spaces in a fully-informed manner. Our aim is to encourage and support therapeutic innovation in the biopharmaceutical sector, as well as academic centers of excellence, through early stage capital investment and the provision of access to the resources of a multinational pharmaceutical company. TVI's mission is to identify, help create and support the development of therapeutic innovation that aligns with Takeda’s own strategic imperatives. We do this by investing in technology and product concepts, and highly effective teams that can turn ideas into reality. Our primary focus is on medium to longer term returns in the form of product and technology successes for our portfolio companies and capital gains for the financial institutions we work with. As a Pharma strategic investor, TVI aims to provide support and guidance to entrepreneurs and early-stage companies driving concepts from preclinical through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. TVI is based in Palo Alto, California and is actively seeking global investment opportunities. Our goal is to build a portfolio of strategic investments, with an immediate emphasis on cardiometabolic, central nervous system, chronic inflammatory and immune modulation, and oncology therapeutic domains. Our focus also includes gastroenterology and renal/urological diseases, as well as innovative platforms for drug target and biomarker identification, regenerative medicines, innovative vaccines technologies and delivery systems for novel protein and peptide therapeutics. TVI currently does not invest in diagnostics platforms, medical technology and devices or anti-infective products.

Address: 435 Tasso Street, Suite 300, Palo Alto, CA 94301, USA

Phone: +1 650 328 2900
FAX: +1 650 328 2922